The deal, which is designed to leverage the expertise and experience from both the companies to optimize Biogen Idec’s clinical development processes, is structured to increase clinical trial efficiency, with a focus on transparency, quality, innovation and operational excellence.
As part of the deal, a dedicated team from Quintiles will work with Biogen Idec on the design, planning and execution of Biogen Idec’s Phase II-IV trials and select Phase I trials.
Additionally, Biogen Idec will leverage Quintiles’ technology and systems across its growing portfolio.
Quintiles chief executive officer Tom Pike said the partnership with Biogen Idec exemplifies the ongoing evolution of drug development collaboration and reinforces the increasingly important role that biopharmaceutical service providers such as Quintiles have in these efforts.
"We are extremely excited about this agreement and the increased interest we are seeing for these types of innovative development deals," Pike said.
"We believe Quintiles is uniquely positioned to help our customers improve their probability of success through these collaborations, and we look forward to working closely with Biogen Idec."
New projects have already been started under the collaboration, and several of Biogen Idec’s ongoing studies are currently transitioning to Quintiles.